Topical Drug Delivery Market 2018-2023 Latest Technology Trends and Future Scope with Top Key Players- GLAXOSMITHKLINE, GALDERMA, BAYER, VALEANT PHARMACEUTICALS, NOVARTIS, MEDPHARM AND HISAMITSU PHARMACEUTICALS

The Topical Drug Delivery Market is expected to witness a CAGR of 9.5%, during the forecast period. North America has been accounted for the highest market share as compared to the other regions.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/17005
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

High Prevalence of Skin Diseases
The prevalence of skin infections, like eczema, psoriasis, etc. and minor ailments, like acne are increasing and having a big impact on the market globally. Psoriasis affect is observed in people of all ages, and in all countries. The reported prevalence of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis a serious global problem with at least 100 million individuals getting affected worldwide. Around 7.5 million US people are getting affected according to the American Academy of Dermatology (AAD). Hence, these statistics shows that the skin diseases prevalence is increasing at a faster pace, which is likely to impact positively on the growth of topical drug delivery market.
The other factor that drives the market includes the ease of drug delivery, approval of new drugs and technological advances and innovations.

Key Developments in the Market
February 2018 - ValeantPharmaceuticals has entered into a licensing agreement with the Kaken Pharmaceutical Co., Ltd., to develop and commercialize new chemical entity, KP-470 for Psoriasis

Major players-
GLAXOSMITHKLINE, GALDERMA, BAYER, VALEANT PHARMACEUTICALS, NOVARTIS, MEDPHARM AND HISAMITSU PHARMACEUTICALS, amongst others.

Get Quality Discount @ https://marketprognosis.com/discount-request/17005
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

High Frequency of Product Recalls
In 2017, Philips recalled many of products such as Tetrastem, Diabecline, Tetracycline-ABC, VenomX, Acneen, StaphWash, StringMed, NoPain, and LidoMed. These all products were being recalled after an FDA inspection as they found significant manufacturing practices that calls into question the safety, identity, strength, quality, and purity of unexpired drug products made by the firm during the past three years. This has an impact on the safety and efficacy of the product posing a risk to the patients. Also, this has posed a negative impact on the sales of the topical drug delivery devices, which is likely to restrain the growth of the market in the coming years.
The other factor, which is also restraining the market, is the regulatory scenario and pricing pressure.

North America is expected to dominate the Market
North America has been accounted for the highest share in the market due to the presence of large number of pharmaceutical companies and drug delivery technology providers. On the other hand Asia Pacific is also likely to register a healthy growth rate in the coming future. The increasing geriatric population and the rising disposable income are few of the factors, which are expected to accelerate the growth of the Asia Pacific market in the coming years.

Browse Report @ https://marketprognosis.com/enquiry/17005
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.